ARQT Stock: Price, Earnings History and SEC Filings
Arcutis Biotherapeutics, Inc. (ARQT) last traded at $32.07, up 0.31% on the latest session and up 21.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.11 against an analyst estimate of $0.09, a beat of 22.2%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ARQT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.11 | $0.09 | +22.22% |
| Mar 2026 | May 6, 2026 | $-0.09 | $-0.02 | -350.00% |
| Dec 2025 | Feb 25, 2026 | $0.13 | $0.03 | +333.33% |
| Sep 2025 | Oct 28, 2025 | $0.06 | $-0.10 | +160.00% |
ARQT beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How ARQT reacts to earnings
Across its last 8 earnings releases, ARQT moved 8.1% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | -2.47% |
| 2026-02-25 | After close | +5.78% |
| 2025-10-28 | Before open | +27.04% |
| 2025-08-06 | After close | -8.07% |
| 2025-05-06 | After close | -4.33% |
| 2025-02-25 | After close | +8.36% |
| 2025-01-13 | Before open | -1.30% |
| 2024-11-06 | After close | +7.66% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ARQT financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $372M | -$16M | -$6M | -4.3% | $-0.13 |
| 2024 | $167M | -$140M | -$112M | -84.1% | $-1.16 |
| 2023 | $29M | -$262M | -$247M | -898.2% | $-3.78 |
| 2022 | $4M | -$311M | -$258M | -8449.8% | $-5.66 |
| 2021 | $0 | -$206M | -$176M | – | $-4.18 |
| 2020 | $0 | -$136M | -$113M | – | $-3.80 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ARQT
- 8-K · Oct 28, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Officer or director change, Financial statements and exhibits
- 8-K · Jul 16, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 9, 2026Shareholder vote, Other events, Financial statements and exhibits
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Financial statements and exhibits
- DEF 14A · Apr 21, 2026
- 10-K · Feb 25, 2026
- 8-K · Feb 25, 2026Results of operations, Financial statements and exhibits
Insider filing activity
ARQT insiders filed 13 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ARQT news
- Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?Oct 29, 2026 · finance.yahoo.com
- Arcutis Biotherapeutics Adds Veteran Leader to BoardOct 29, 2026 · theglobeandmail.com
- Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings GrowthOct 28, 2026 · finance.yahoo.com
- Arcutis Appoints Rob Scott, MD to Board of DirectorsOct 28, 2026 · finance.yahoo.com
- Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceOct 27, 2026 · finance.yahoo.com
- Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026Oct 21, 2026 · finance.yahoo.com
- Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares ClimbOct 20, 2026 · finance.yahoo.com
- Clinical Data Update Could Shape The Case For Arcutis Biotherapeutics StockOct 19, 2026 · finance.yahoo.com
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.